Old Web
English
Sign In
Acemap
>
authorDetail
>
Ryan Geschwindt
Ryan Geschwindt
Incyte
Medicine
Placebo
Cancer research
Capecitabine
Breast cancer
2
Papers
19
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
419 Pharmacodynamic biomarkers demonstrate T-cell activation in patients treated with the oral PD-L1 inhibitor INCB086550 in a phase 1 clinical trial
2020
Journal for ImmunoTherapy of Cancer
Sarina Anne Piha-Paul
Tara C. Mitchell
Solmaz Sahebjam
Janice M. Mehnert
Thomas Benjamin Karasic
Kevin O’Hayer
Ryan Geschwindt
Susan Spitz
Hao Liu
Johanna C. Bendell
Show All
Source
Cite
Save
Citations (0)
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation
2018
Breast Cancer Research and Treatment
Joyce O’Shaughnessy
Angela DeMichele
Cynthia X. Ma
P. G. Richards
Denise A. Yardley
Gail Shaw Wright
Kevin Kalinsky
Ronald Steis
Sami G. Diab
Gerard Kennealey
Ryan Geschwindt
Wei Jiang
Hope S. Rugo
Show All
Source
Cite
Save
Citations (19)
1